ERA

Endometrial Receptivity Analysis

Evaluates the status of the woman’s endometrial receptivity to prevent implantation failure

Scroll Down

Overview

  • ERA is a diagnostic test patented by IGENOMIX in 2009 that helps to evaluate the woman’s endometrial receptivity.
  • ERA identifies a patient’s unique “window of implantation” (WOI) leading to a personalized embryo transfer (pET).
  • 3 in every 10 patients have a displaced WOI. In such cases, a second endometrial biopsy is needed to identify when the patient is receptive.

More info

img_cercle-11.png

An endometrium is receptive when it is ready for embryo implantation. This occurs around days 19-21 in each menstrual cycle of a fertile woman. This period of receptivity is what we call the window of implantation.

The lack of synchronisation between the embryo ready to be implanted and endometrial receptivity is one of the causes of recurring implantation failure. This is why it is imperative to assess the endometrium in order to determine the optimal day for embryo transfer.

The ERA test requires an endometrial biopsy that should be carried out on day LH+7 (natural cycle) or day P+5 (HRT cycle). This biopsy is quickly and easily taken by a gynaecologist in their consultation room and sent to Igenomix for testing
The ERA test analyses the expression levels of 236 genes linked to the status of endometrial receptivity, using RNA sequencing taken from the endometrial tissue.

Following the analysis, a specific computational predictor classifies the samples according to their expression profile as Receptive or Non-Receptive.

 

The Endometrial Receptivity Anaysis (ERA®) has been designed, developed and patented by IGENOMIX (PCT/ES2009/000386)..

Benefits

  • ERA identifies the window of implantation (WOI) and recommends the best time for embryo transfer thereby increasing the chances of a successful outcome.
  • The ERA test has proven highly sensitive and accurate in detecting gene expression profiles associated with endometrial receptivity.
  • ERA improved pregnancy rates up to 85% following personalized embryo transfer made according to ERA test results*.

(*SREI Prize Paper 2016. 0-115 Simón et al. on behalf of the ERA RCT Consortium.)

Indications

    • Women who have experienced implantation failures with morphologically good quality embryos.
    • Women with a morphologically normal uterus and normal endometrial thickness (≥ 6 mm), where the uterus and endometrium are unlikely to be the problem.


ERA-Indications.png
img_cercle-05.png

Technology

The ERA test is performed with Next Generation Sequencing (NGS) technology

  • NGS is a scalable technology allowing large numbers of samples to be analyzed simultaneously.
  • NGS flexibility and accuracy has enabled the development of a new, improved predictor tool and will allow us to further enhance the test's effectiveness and include additional diagnostic markers.

More Info

Methodology

ERA-grafico.png

References

Scientific publications and documents.

ERA publications

ERA publications

Other scientific documents

Other scientific documents

Our results

Our experts are professional, reliable and approachable and are available to help guide both professionals and patients throughout the entire process. We are proud to deliver high quality results for every test, every day.

More than

22K

ERA tests performed

54

countries

More than

600

clinics

16

scientific publications

Become our provider

Contact us now and we will guide you through the entire process

CONTACT US